Angiography-derived FFR reduces perioperative events in CABG for valve surgery patients
The FAVOR IV-QVAS trial was a multicentre, triple-blind, randomized controlled trial conducted at 12 tertiary hospitals in China, enrolling 793 patients undergoing surgical valve procedures with concomitant coronary artery disease. Patients were randomized to either physiologically guided CABG using angiography-derived fractional flow reserve (FFR) or anatomically guided CABG based on stenosis severity via coronary angiography. The primary endpoint was a composite of death, myocardial infarction, stroke, unplanned coronary revascularisation, and new renal failure requiring dialysis within 30 days post-surgery. Results showed that the primary outcome occurred in 7.8% of the angiography-derived FFR group versus 13.4% in the coronary angiography group, yielding a risk ratio of 0.58 (95% CI 0.38-0.89, p=0.011). The key secondary outcome, a composite of death, myocardial infarction, stroke, unplanned coronary revascularisation, and hospitalization for unstable angina or heart failure at a median follow-up of 27 months, was also lower in the angiography-derived FFR group (20.7% vs. 26.8%, HR 0.74, 95% CI 0.55-0.98, p=0.036). The study suggests that physiologically guided CABG may offer superior outcomes in this patient population, supporting a shift towards physiological assessment in surgical coronary revascularization strategies. No significant safety concerns were reported, and the trial was funded by the Shanghai Hospital Development Center, Shanghai Municipal Science and Technology Commission, and the Ministry of Science and Technology of the People's Republic of China.